Department of Clinical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.
Thromb Haemost. 2011 Mar;105(3):396-408. doi: 10.1160/TH10-09-0595. Epub 2010 Dec 21.
Results of plasma microparticles (MPs) measurements reported in the literature vary widely. This is clearly not only related to the lack of well-standardised MP assays, but also to variations in pre-analytical conditions. In this review we will discuss the pre-analytical variables related to plasma and MP preparation which may affect MP analysis. Additionally we will address several analytical issues in commonly used MP assays and briefly discuss some novel approaches for the detection and characterisation of MPs. Ideally MP measurements should be performed in plasma, freshly prepared directly after blood withdrawal. As platelet contamination seems to be one of the major pre-analytical problems in processing plasma for MP measurement, the use of platelet-free plasma may be preferred. When frozen-thawed plasma is used, especially PMP and annexinV-positive MP counts should be interpreted with caution. When flow cytometry is chosen as a method for quantification of MPs, some analytical conditions should be standardised, e.g. settings of the flow cytometer, quality of the antibodies, and use of counting beads. Fluorescence-nanoparticle tracking analysis and atomic force microscopy can accurately count nanosized MPs, but unfortunately the operational procedures of both methods are still time consuming and they give no information on the functional properties of MPs. The MP-TF activity assay provides information on MPs carrying active TF, regardless of their parental origin. Ultimately, standardisation of pre-analytical procedures and the introduction of reliable and rapid methods for the measurement of MPs are urgently needed to facilitate their use as biomarker in the pathophysiology of diseases.
文献中报道的血浆微粒(MPs)测量结果差异很大。这显然不仅与缺乏标准化的 MP 检测方法有关,还与分析前条件的变化有关。在这篇综述中,我们将讨论与血浆和 MP 制备相关的分析前变量,这些变量可能会影响 MP 分析。此外,我们还将讨论常用 MPs 检测方法中的几个分析问题,并简要讨论一些用于检测和表征 MPs 的新方法。理想情况下,应在刚从血液中提取后立即在血浆中进行 MP 测量。由于血小板污染似乎是处理血浆进行 MP 测量的主要分析前问题之一,因此可能更倾向于使用无血小板血浆。如果使用冻融血浆,特别是 PMP 和膜联蛋白 V 阳性 MP 计数应谨慎解释。当选择流式细胞术作为 MPs 定量的方法时,一些分析条件应标准化,例如流式细胞仪的设置、抗体的质量以及使用计数珠。荧光纳米颗粒跟踪分析和原子力显微镜可以准确地计数纳米级 MPs,但不幸的是,这两种方法的操作程序仍然很耗时,并且它们不能提供 MPs 功能特性的信息。MP-TF 活性测定法提供了关于携带活性 TF 的 MPs 的信息,而与它们的亲本来源无关。最终,需要标准化分析前程序并引入可靠和快速的 MPs 测量方法,以促进它们在疾病病理生理学中的生物标志物的应用。